Resources/
Phil Blog

Phil Blog

3 Reasons Why Your Patient Services Program May be Falling Short on Medication Adherence

Medication nonadherence is a long-standing problem linked to poor health outcomes, increased hospitalizations, and significantly higher healthcare costs. According to the CDC, out of the 3.8 billion prescriptions written in the U.S., one out of five are never filled. Even with good insurance and drug coverage, medication adherence rates for chronic conditions fall between 50-60%– a far cry from the 80% adherence rates medical experts say are necessary for optimal therapeutic efficacy

4 Strategies to Maximize Enrollment in your Patient Services Program

Low enrollment in manufacturer-sponsored patient services programs is rampant, so much so that many industry stakeholders have come to accept this as inevitable. This disappointing trend nearly always holds true if brands employ traditional “call center-based” hubs or specialty pharmacies that lack consumer-friendliness, creating unnecessary friction for patients and HCPs. These “clunky” programs typically result in enrollment rates between 20-30%

Implementing an Effective Bridge Program: Laying the Foundation for Covered Dispenses

A common challenge for specialty and specialty-lite brand commercialization teams is maximizing prescription coverage while minimizing free goods program overutilization. Patient bridge and quickstart programs, which provide temporary access to medications for patients experiencing coverage gaps or delays, are essential for therapy continuity and preventing financial burden on patients. However, these programs can negatively impact the manufacturers’ bottom line if manufacturers don’t implement the appropriate safeguards and requirements

Phil and Teva Pharmaceuticals Launch New Program to Improve Access

SAN FRANCISCO, Calif. – June 6, 2023 – Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform. Teva’s Digihaler system is the first and only smart inhaler system that can provide objective inhaler data to help patients and their doctors have informed treatment discussion in support of asthma management

Launching a New Drug in a Category with Generic Alternatives

Getting an innovative prescription drug approved for patient use is a significant milestone – however, it's only the beginning and certainly does not ensure the brand's commercial success. Considering it typically takes ten years and over $2.6 billion for a life sciences manufacturer to move a drug from its initial discovery into the marketplace, commercialization teams must employ effective launch strategies that differentiate their brand to get it into the hands of patients. Launching into a category with generic alternatives presents a unique challenge because payers often limit patients' access to the new entrant through utilization management tools that favor the lower-cost generics